OraSure Technologies Q3 2026: Revenue Grows 14% After Six Quarters of Decline

As seen on the 24/7 Wall St. homepage on November 9, 2026.

OSUR OraSure Technologies
Q3 2026
EPS
-$0.15
est -$0.18 +16.7%
Revenue
$31M
est $31M -0.4%

Revenue grew 14% year over year, the first real sign the core business has stopped shrinking after six quarters of decline. Non-GAAP gross margin expanded to 45.9%, narrowing the loss versus expectations even though revenue slightly missed. Management guided Q4 to $30 million to $32 million.

OSUR share price +0.00% since close
$3.6$3.6$3.5 Q3 2026 filed
Continue ReadingShow less

OraSure Technologies reported Q3 2026 revenue of $30.9 million, up 14% year over year, marking the first meaningful top-line rebound after six consecutive quarters of decline. Growth came from both major segments: Diagnostics on stronger HIV and HCV test volumes plus the addition of BioMedomics' Sickle SCAN sales, and Sample Management Solutions on key commercial customer growth.

On the bottom line, the company posted an adjusted loss of $0.15 per share, beating the consensus estimate of $0.18. The outperformance was driven in part by non-GAAP gross margin expanding to 45.9% from 44.2% a year earlier, as operational efficiencies improved fixed-overhead absorption. Revenue came in just under the $31.02 million analyst target, missing expectations by less than half a percent.

Two new products reached commercial launch during the quarter: the OraQuick Ebola 2.0 Rapid Antigen Test, capable of detecting four strains of the Ebola virus, and the Colli-Pee Dx Urine Collection Kit, cleared for use with Roche cobas STI tests. CEO Carrie Eglinton Manner noted that both saw initial orders shortly after launch, describing the milestones as part of a broader push to decentralize diagnostics and make testing more accessible and private.

Sponsored

For Q4 2026, management guided revenue of $30 million to $32 million and indicated it expects year-over-year growth to accelerate further in full-year 2027. Cash and equivalents stood at $148.2 million at the end of the quarter, down from $199.3 million at year-end 2025, reflecting continued operating losses as the company invests in its growth initiatives. The operating loss for the quarter was $13.0 million.

After peaking near $39.9 million in Q3 2024, revenue fell steadily through Q3 2025 and Q4 2025 before beginning to recover. Q3 2026 at $30.9 million represents the highest quarterly figure since that recovery began, and the Q4 guidance midpoint of $31 million would sustain that level heading into 2027.

Mentioned: OSUR